Clinical Trial Update: Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene [Phase 1, Phase 2]

View source ↗

Summary

An NCI-sponsored clinical trial is evaluating the safety of CX-5461 (Pidnarulex) in lymphomas with MYC alterations, including Burkitt lymphoma and double-expres…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Double Expressor Lymphoma
• High-grade B-cell Lymphoma with Myc and Bcl2 and or Bcl6 Rearrangements

Drugs mentioned

• Pidnarulex (CX-5461)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Burkitt Lymphoma, Double-Expressor Lymphoma | Phase 1, Phase 2 | Status: RECRUITING